Today: 30 April 2026
Qualcomm (QCOM) stock price dips as new target cuts flag weaker 2026 handset demand
27 January 2026
2 mins read

Qualcomm (QCOM) stock price dips as new target cuts flag weaker 2026 handset demand

New York, January 27, 2026, 15:15 EST — Regular session

  • Qualcomm shares slipped roughly 0.5% in afternoon trading, lagging behind some other chip stocks.
  • Mizuho lowered its price target to $160, pointing to weaker handset shipments in 2026 and increased competition.
  • Investors will be focused on the Fed’s decision set for Jan. 28, along with Qualcomm’s earnings report due Feb. 4.

Qualcomm shares dipped 0.5% to $153.76 in afternoon trading Tuesday, erasing earlier gains as investors digested new target cuts amid a weaker smartphone forecast.

This shift is crucial as Qualcomm faces a tricky period ahead: the Federal Reserve’s policy decision looms, which could shake rate-sensitive tech shares, alongside Qualcomm’s earnings report next week. The stock’s behavior lately resembles that of a handset proxy once more, with analysts increasingly focused on the durability of 2026 phone volume forecasts.

Mizuho on Monday lowered its price target to $160 from $175, maintaining a Neutral rating. The brokerage forecasts global handset shipments to drop around 4% in 2026, with risks pushing that decline beyond 5%. It highlighted rising competition from MediaTek and noted what it described as content cuts by Apple and Huawei. Mizuho also cited tighter memory supply and higher prices, which are weighing on Android manufacturers and China’s original design manufacturers (ODMs) that assemble phones for brands.

UBS lowered its price target to $160 from $185 but maintained a Neutral rating, according to a report released Monday.

Qualcomm slipped even as other chip stocks showed strength, boosted by a rotation into the sector after Micron’s announcement of a $24 billion investment in Singapore. Markets remain uneven ahead of the Fed’s decision, with investors weighing if easing inflation will prompt rate cuts later this year.

Off the main tape, Qualcomm’s venture arm quietly backed “on-device” AI—a type of software that processes data locally instead of relying on the cloud. SpotDraft announced it secured $8 million from Qualcomm Ventures in a strategic extension of its Series B round. The funds will help scale contract-review tools optimized for Snapdragon processors. “We’re excited to enable high-performance, secure AI at the edge,” said Quinn Li, senior vice president at Qualcomm Technologies and global head of Qualcomm Ventures, in a statement. Business Wire

Qualcomm, widely recognized for its modem and application chips powering smartphones, also earns significant revenue through wireless patent licensing. While it has expanded into PCs, autos, and other connected gadgets, smartphones remain the primary source of its chip sales.

Bulls face a clear risk: if handset sales drop more than anticipated or pricing pressure intensifies, earnings could weaken, dragging the stock down—even if the wider chip sector rallies. Competition in premium Android chips adds another layer of uncertainty, and guidance often shifts this stock’s direction more than the actual quarterly results.

Macro factors could lead. The Fed’s two-day session is set for Jan. 27-28, with a policy statement due at 2:00 p.m. ET Wednesday, followed by a press briefing at 2:30 p.m. ET.

Qualcomm will release its fiscal first-quarter results after markets close on Feb. 4, followed by a conference call at 1:45 p.m. Pacific time. Investors are focused on guidance around handset demand and any insights on the company’s AI strategy.

Stock Market Today

  • Catalyst Pharmaceuticals (CPRX) Shares Gain, Valuation Below Biotech Peers
    April 29, 2026, 9:28 PM EDT. Catalyst Pharmaceuticals (CPRX) shares rose to $28.26, up nearly 9% in a week and 19% over 30 days, drawing investor focus on its valuation amid rare disease drug development. The stock trades at a price-to-earnings (P/E) ratio of 16.1 times, below the biotech peer average of 33.4 but slightly above an estimated fair P/E of 15.2, signaling modest undervaluation. Despite strong long-term returns, the market appears cautious, pricing in growth risks linked to Catalyst's niche focus. Investors must weigh the discounted valuation against potential changes in earnings expectations and sector sentiment.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy
Previous Story

ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

ASTS stock price rises as AST SpaceMobile’s 2026 launch pace comes back under the microscope
Next Story

ASTS stock price rises as AST SpaceMobile’s 2026 launch pace comes back under the microscope

Go toTop